メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
北村 寛
教授, 博士（医学） 札幌医科大学 2006年3月
腎泌尿器科学講座
h-index
4307
被引用数
33
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
1996 …
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
プロジェクト
(2)
研究成果
(122)
コース
(6)
類似のプロファイル
(6)
フィンガープリント
Hiroshi Kitamuraが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Transitional Cell Carcinoma
86%
Prostate Cancer
79%
Overall Survival
73%
Cystectomy
66%
Bladder Cancer
65%
Neoplasm
50%
Disease
47%
Non Muscle Invasive Bladder Cancer
44%
Prognostic Factor
43%
Chemotherapy
41%
Malignant Neoplasm
41%
Retrospective Study
40%
Pembrolizumab
38%
Recurrent Disease
36%
Prostatectomy
31%
Metastatic Carcinoma
30%
Transurethral Resection
29%
Retroperitoneal Lymph Node Dissection
26%
Urothelial Cancer
26%
Robot-Assisted Prostatectomy
26%
Kidney Metastasis
24%
Lymph Node
23%
Multivariate Analysis
23%
Cohort Analysis
21%
Bladder
20%
Computer Assisted Tomography
20%
Progression Free Survival
19%
Pelvis
19%
Muscle Invasive Bladder Cancer
19%
Hazard Ratio
18%
Nivolumab
18%
Prostate Specific Antigen
17%
Cisplatin
17%
Cancer Specific Survival
17%
Survival Rate
16%
Lymph Node Metastasis
16%
Partial Nephrectomy
16%
Biopsy Technique
15%
Bone Metastasis
15%
Germinoma
14%
Survivin
14%
Cancer Cell
14%
Adverse Event
14%
Recurrence Free Survival
13%
Lymphocyte
13%
Mycobacterium Bovis BCG
13%
Nephrectomy
13%
Proportional Hazards Model
12%
Castration Resistant Prostate Cancer
12%
Keyphrases
Renal Cell Carcinoma
81%
Overall Survival
55%
Bladder Cancer
51%
Radical Cystectomy
51%
Prostate Cancer
50%
Urothelial Carcinoma
48%
Japan
47%
Non-muscle Invasive Bladder Cancer (NMIBC)
45%
Pembrolizumab
40%
Metastatic Renal Cell Carcinoma (mRCC)
39%
Prognostic Factors
32%
Bacillus Calmette
30%
Robot-assisted Radical Prostatectomy
26%
Urothelial Cancer
25%
Confidence Interval
25%
Metastatic Urothelial Carcinoma
25%
Radical Prostatectomy
24%
Metastasis
23%
Oncological Outcomes
22%
Multivariate Analysis
22%
Upper Tract Urothelial Carcinoma
21%
Cancer-specific Survival
21%
Progression-free Survival
21%
Advanced Urothelial Carcinoma
21%
Tumor
20%
Clinical Practice Guidelines
19%
Muscle-invasive Bladder Cancer
19%
Intravesical
19%
Chemotherapy
19%
Multicenter Cohort Study
18%
Bone Metastasis
18%
Hazard Ratio
18%
Cisplatin
18%
Multi-institutional
18%
Lymph Node Metastasis
16%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
16%
Cancer Patients
16%
Transurethral Resection
16%
Median Overall Survival
16%
Clinical Outcomes
15%
Multicenter Retrospective Study
15%
Nivolumab
15%
Clear Cell Renal Cell Carcinoma (ccRCC)
15%
Older Patients
15%
Prostate
14%
Advanced Renal Cell Carcinoma
14%
Castration-resistant Prostate Cancer
14%
Computed Tomography
14%
Poor Prognosis
14%
After Surgery
14%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
57%
Renal Cell Carcinoma
55%
Overall Survival
55%
Malignant Neoplasm
53%
Transitional Cell Carcinoma
49%
Disease
36%
Non Muscle Invasive Bladder Cancer
34%
Neoplasm
29%
Retrospective Study
29%
Kidney Metastasis
26%
Chemotherapy
26%
Progression Free Survival
25%
Bladder Cancer
25%
Pembrolizumab
23%
Recurrent Disease
22%
Castration Resistant Prostate Cancer
21%
Nivolumab
18%
Cisplatin
18%
Adverse Event
18%
Survival Rate
14%
Axitinib
13%
Prostate Specific Antigen
13%
Immunotherapy
12%
Bone Metastasis
11%
Androgen
11%
Cancer Specific Survival
11%
Sunitinib
10%
Clinical Study
10%
Survivin
10%
Gemcitabine
9%
Mycobacterium Bovis BCG
8%
Germ Cell Tumor
8%
Recurrence Free Survival
8%
Paclitaxel
7%
Prednisolone
7%
Protein Tyrosine Kinase Inhibitor
7%
Combination Therapy
7%
Gleason Score
7%
Hypoxia Inducible Factor Proline Dioxygenase
7%
Procollagen Proline 2 Oxoglutarate 4 Dioxygenase
7%
Scatter Factor
7%
Vinblastine
6%
Methotrexate
6%
Doxorubicin
6%
Biochemical Recurrence
6%
Docetaxel
6%
Monotherapy
6%
Ipilimumab
6%
Cohort Study
6%
Anticarcinogen
5%
